Free Trial

Xencor (XNCR) Competitors

Xencor logo
$9.31 +0.07 (+0.71%)
As of 02:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XNCR vs. APLS, XENE, NAMS, GMTX, BHC, AGIO, TWST, INDV, RXRX, and DNLI

Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Indivior (INDV), Recursion Pharmaceuticals (RXRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

Xencor vs. Its Competitors

Xencor (NASDAQ:XNCR) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Xencor has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 4.8% of Xencor shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xencor presently has a consensus target price of $28.00, indicating a potential upside of 200.88%. Apellis Pharmaceuticals has a consensus target price of $40.00, indicating a potential upside of 103.86%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Apellis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Apellis Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.62

In the previous week, Apellis Pharmaceuticals had 10 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 1 mentions for Xencor. Xencor's average media sentiment score of 1.89 beat Apellis Pharmaceuticals' score of 0.61 indicating that Xencor is being referred to more favorably in the media.

Company Overall Sentiment
Xencor Very Positive
Apellis Pharmaceuticals Positive

Apellis Pharmaceuticals has higher revenue and earnings than Xencor. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$127.23M5.21-$232.62M-$3.06-3.04
Apellis Pharmaceuticals$775.84M3.18-$197.88M-$1.79-10.96

Apellis Pharmaceuticals has a net margin of -28.83% compared to Xencor's net margin of -181.17%. Xencor's return on equity of -31.94% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-181.17% -31.94% -22.19%
Apellis Pharmaceuticals -28.83%-99.19%-25.35%

Summary

Apellis Pharmaceuticals beats Xencor on 9 of the 17 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XNCR vs. The Competition

MetricXencorMED IndustryMedical SectorNASDAQ Exchange
Market Cap$657.62M$2.76B$5.71B$9.51B
Dividend YieldN/A1.78%4.60%3.99%
P/E Ratio-3.029.0628.0720.02
Price / Sales5.21744.11459.47103.02
Price / CashN/A166.2336.5558.97
Price / Book0.975.188.615.88
Net Income-$232.62M$30.99M$3.24B$258.50M
7 Day Performance3.75%7.26%3.83%2.03%
1 Month Performance8.71%15.66%10.40%12.52%
1 Year Performance-56.25%-1.06%34.13%19.07%

Xencor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XNCR
Xencor
4.5069 of 5 stars
$9.31
+0.7%
$28.00
+200.9%
-54.7%$657.62M$127.23M-3.02280Positive News
APLS
Apellis Pharmaceuticals
4.2298 of 5 stars
$19.91
+2.4%
$39.79
+99.8%
-46.3%$2.50B$781.37M-11.12770Upcoming Earnings
XENE
Xenon Pharmaceuticals
3.7513 of 5 stars
$32.60
+1.2%
$54.82
+68.2%
-29.1%$2.50B$9.43M-10.09210Positive News
Options Volume
NAMS
NewAmsterdam Pharma
3.7852 of 5 stars
$22.17
+2.9%
$42.89
+93.5%
+23.8%$2.49B$47.14M-11.794
GMTX
Gemini Therapeutics
N/A$56.91
-1.9%
N/A+32.1%$2.47BN/A-56.9130
BHC
Bausch Health Cos
3.4604 of 5 stars
$6.34
-1.3%
$7.30
+15.2%
+16.6%$2.34B$9.63B-57.5920,700Upcoming Earnings
AGIO
Agios Pharmaceuticals
4.3441 of 5 stars
$39.23
+0.5%
$58.60
+49.4%
-17.7%$2.27B$37.04M3.49390Upcoming Earnings
Analyst Forecast
TWST
Twist Bioscience
4.3689 of 5 stars
$37.80
-0.6%
$50.40
+33.3%
-37.4%$2.26B$312.97M-11.63990Positive News
INDV
Indivior
1.1562 of 5 stars
$15.62
+1.0%
$17.00
+8.8%
+54.5%$2.15B$1.17B-50.391,051News Coverage
Analyst Forecast
RXRX
Recursion Pharmaceuticals
1.4367 of 5 stars
$5.28
flat
$7.00
+32.6%
-19.8%$2.15B$59.82M-2.98400
DNLI
Denali Therapeutics
4.2552 of 5 stars
$14.69
+1.2%
$33.71
+129.5%
-39.4%$2.13B$330.53M-5.50430News Coverage
Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:XNCR) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners